Sep 27, 2023
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
Additional Formats
Sep 26, 2023
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
Additional Formats
Sep 06, 2023
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Additional Formats
Aug 10, 2023
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Additional Formats
Aug 02, 2023
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Additional Formats
Jun 13, 2023
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
Additional Formats
Jun 08, 2023
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
Additional Formats
Jun 05, 2023
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Additional Formats
May 19, 2023
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Additional Formats
May 11, 2023
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Additional Formats
Displaying 1 - 10 of 15